Calidi Biotherapeutics (CLDI) Other financing activities (2022 - 2025)
Calidi Biotherapeutics' quarterly Other financing activities came in at $121000.0 in Q4 2025, down 75.9% year-on-year from $502000.0 in Q4 2024, and down 64.83% quarter-over-quarter from $344000.0 in Q3 2025.
Calidi Biotherapeutics has reported Other financing activities for 4 years, with the latest figure at $121000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other financing activities fell 75.9% year-over-year to $121000.0; the trailing twelve-month figure through Dec 2025 stood at $846000.0 (down 45.56% YoY), and the FY2025 full-year result was $846000.0, down 45.56% from the prior year.
- Other financing activities for Q4 2025 stood at $121000.0, down from $344000.0 in the prior quarter.
- The five-year high for Other financing activities was $1.5 million in Q1 2022, with the low at $71000.0 in Q1 2023.
- Average Other financing activities over 4 years is $475692.3, with a median of $344000.0 recorded in 2025.
- Year-over-year, Other financing activities plunged 95.16% in 2023 and surged 128.17% in 2024.
- Tracing CLDI's Other financing activities over 4 years: stood at $1.5 million in 2022, then plunged by 54.98% to $660000.0 in 2023, then decreased by 23.94% to $502000.0 in 2024, then plunged by 75.9% to $121000.0 in 2025.
- The last three Other financing activities figures came in at $121000.0 (Q4 2025), $344000.0 (Q3 2025), and $80000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn |
| 10 | Calidi Biotherapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 121,000.00 |
| Dec 31, 2025 | 121,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Sep 30, 2025 | 344,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 80,000.00 |
| Mar 31, 2025 | 301,000.00 |
| Mar 31, 2025 | 301,000.00 |
| Dec 31, 2024 | 502,000.00 |
| Dec 31, 2024 | 502,000.00 |
| Sep 30, 2024 | 271,000.00 |
| Sep 30, 2024 | 271,000.00 |
| Jun 30, 2024 | 619,000.00 |
| Jun 30, 2024 | 619,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Dec 31, 2023 | 660,000.00 |
| Dec 31, 2023 | 660,000.00 |
| Sep 30, 2023 | 507,000.00 |
| Sep 30, 2023 | 507,000.00 |
| Jun 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | 71,000.00 |
| Mar 31, 2023 | 71,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.47 Mn |